Optimized alkylated cyclodextrin polysulphates with reduced risks on thromboembolic accidents improve osteoarthritic chondrocyte metabolism

Sara Groeneboer1, Stijn Lambrecht1, Aad Dhollander1, Peggy Jacques1, Bert Vander Cruyssen1, Rik J. Lories2, Katrien Devreese3, Koen Chiers4, Dirk Elewaut1 and Gust Verbruggen1

Abstract

Objectives. To compare the ability of different cyclodextrin polysulphate (CDPS) derivatives to affect human articular cartilage cell metabolism in vitro.

Methods. OA chondrocytes were cultured in alginate and exposed to 5 μg/ml of 2,3,6-tri-O-methyl-β-cyclodextrin (ME-CD), 2,3-di-O-methyl-6-sulphate-β-cyclodextrin (ME-CD-6-S), 2,6-di-O-methyl-3-sulphate-β-cyclodextrin (ME-CD-3-S), (2-carboxyethyl)-β-CDPS (CE-CDPS), (2-hydroxypropyl)-β-CDPS (HP-CDPS), 6-monoamino-6-monodeoxy-β-CDPS (MA-CDPS) or β-CDPS for 5 days. Effects on IL-1-driven chondrocyte extracellular matrix (ECM) metabolism were assayed by analysis of the accumulation of aggrecan in the interterritorial matrix, IL-6 secretion and qPCR. MA-CDPS, HP-CDPS, CE-CDPS and CDPS were analysed for their in vitro effect on coagulation and their ability to activate platelets in an in vitro assay to detect possible cross-reactivity with heparin-induced thrombocytopenia (HIT) antibodies.

Results. The monosulphated cyclodextrins ME-CD-6-S and -3-S failed to affect aggrecan synthesis and IL-6 secretion by the OA chondrocytes. Polysulphated cyclodextrins MA-CDPS, HP-CDPS, CE-CDPS and CDPS at 5 μg/ml concentrations, on the other hand, significantly induced aggrecan production and repressed IL-6 release by the chondrocytes in culture. aPTT and PT for all derivatives were lengthened for polysaccharide concentrations >50 μg/ml. Five micrograms per millilitre of β-CDPS concentrations that significantly modulated ECM ground substance production in vitro did not affect aPTT or PT. Furthermore, CE-CDPS, in contrast to MA-CDPS, HP-CDPS and CDPS, did not significantly activate platelets, suggesting a minimal potential to induce HIT thromboembolic accidents in vivo.

Conclusions. CE-CDPS is a new, structurally adjusted, sulphated β-cyclodextrin derivative with preserved chondroprotective capacity and a promising safety profile.

Key words: Chondroprotection, Osteoarthritis, Cyclodextrin polysulphates.

Introduction

OA is characterized by the degeneration and eventual loss of cartilage with concurrent changes in the subchondral bone. While it is generally accepted that mechanical stress may result in the damage that will set off the OA process, its progression involves the activities of multiple auto/paracrine cytokine activities. IL-1 is believed to be a major regulator of matrix degradation by increasing metalloproteinase activity and suppressing the synthesis of matrix components. In addition to significantly higher intracellular levels of IL-1β, chondrocytes from fibrillated cartilage show an up-regulation of the signalling IL-1
receptor I (IL-1RI) levels compared with normal cartilage [1]. Despite the attempt of chondrocytes to restore the homeostasis of their matrix by enhancing insulin-like growth factor 1 (IGF-1) and TGF-β growth factor activity [2, 3], the catabolic activity of the OA chondrocyte results in a continuous net loss of matrix components ensuing disease progression.

The search for agents that restore the structural deficiencies underlying OA started in the mid-1970s with the findings that sulphated polysaccharides, e.g. heparin and chondroitin sulphates, with varying degrees of sulphating, enhanced the synthesis of extracellular matrix (ECM) substances by connective tissue cells in culture [4, 5]. In particular, the polysulphated polysaccharides provided significant effects on the structure and function of articular cartilage cells in culture [6, 7]. These effects were also observed in vivo [8-10]. Consequently, both xyllosan polysulphate and chondroitin polysulphate found their place in the treatment of osteoarticular pathology in veterinary and in human medicine, respectively.

Apart from the chondroprotective capacities, however, these polysulphated polysaccharides were revealed to possess important biological activities similar to those of heparin. Such biological activities were clearly shown to be related to the molecular structure of the polysaccharide heparin. Such biological activities were clearly shown to these polysulphated polysaccharides were revealed to in the treatment of osteoarticular pathology in veterinary sulphate and chondroitin polysulphate found their place in culture [6, 7]. These effects were also observed in vivo [8-10]. Consequently, both xyllosan polysulphate and chondroitin polysulphate found their place in the treatment of osteoarticular pathology in veterinary and in human medicine, respectively.

Apart from the chondroprotective capacities, however, these polysulphated polysaccharides were revealed to possess important biological activities similar to those of heparin. Such biological activities were clearly shown to be related to the molecular structure of the polysaccharide and varied following distinct modifications. In vitro and in vivo studies on the effects of these polysaccharides on coagulation showed variable effects on thrombin clotting times. It was, however, the possibility of such polysulphated polysaccharides to induce heparin-induced thrombocytopenic thrombosis (HITT) through cross-reaction with heparin/platelet factor-4 antibodies that had raised serious concern [11]. These antibodies arise occasionally when activated thrombocytes release platelet factor-4 (PF4) during heparin treatment. Heparin then forms a complex with PF4 that acts as an antigen which triggers the production of auto-antibodies. These antibodies bind to the complex via their F(ab) region and to the low affinity immunoglobulin gamma Fc region receptor II-b (FcγRII) [immunoglobulin G (IgG) CD32] of other platelets via their Fc portion, thereby initiating platelet activation, aggregation and thromboembolic accidents [12]. It has been shown that some low-molecular weight heparins as well as other sulphated polysaccharides, e.g. chondroitin polysulphates [13], can also bind to heparin-induced thrombocytopenia (HIT) antibodies in the presence of PF4 and that their reactivity is dependent on their molecular weight and the sulphating grade [12, 14, 15].

When, in the 1980s, controversial reports on the occurrence of HIT following treatment with chondroitin polysulphate came out [13], national and international agencies for the evaluation of medicinal products insisted that the previous manufacturer of this polysulphated chondroitin (Arteparon; Luitpold Werk, München, Germany) provided the conventional drug master files confirming the claims on efficacy and safety of that drug in human clinics. As the patent life of chondroitin polysulphate had gone, the manufacturer at that time did not respond to this demand and the European formulation of chondroitin polysulphate was taken off the market in 1994. Neutraceutical industries then introduced the naturally occurring chondroitin sulphate to replace chondroitin polysulphate for the use in degenerative joint disease in humans. In the sole head-to-head confrontation thus far, the naturally occurring chondroitin sulphate was inferior to chondroitin polysulphate when the chondroprotective effects of both drugs were assessed in a population with hand OA [16].

Recently, a novel polysulphated polysaccharide, cyclo-dextrin polysulphate (CDPS) was reported to induce a down-regulation of intracellular IL-1α and -β and to cause a concomitant increase in the synthesis of aggregan, collagen Type II and fibronectin in the cell-associated matrix (CAM) of human chondrocytes cultured in alginate beads [17]. This CDPS also depressed the IL-6 release of OA chondrocytes by 60% compared with untreated OA cartilage cells and equalled the levels secreted by normal cells [17].

CDPS, subcutaneously administered in a rabbit model of experimental OA, reduced the cartilage lesions and osteophyte formation in the affected joints [18]. These data suggest that CDPS positively affects the tissue pathology underlying OA and this agent can therefore be classified as a structure or disease-modifying OA drug.

To alleviate possible heparin-related side effects, we have developed six sulphated β-cyclodextrin derivatives by introducing hydrophobic substituents on the 2, 3 and/or 6 position, assuming they would preserve their chondroprotective effect. Next, the effect on coagulation and the potency to induce thrombocytopenia through cross-reaction with heparin/PF4 antibodies were assayed. Once optimized, these derivatives were tested for their capacity to restore cartilage damage in vivo.

Materials and methods

β-Cyclodextrin derivatives

The 2,3,6-tri-O-methyl-β-cyclodextrin (ME-CD) was purchased from Cyclolab Ltd (Budapest, Hungary) and served as a non-sulphated control molecule. β-Cyclodextrins carrying one sulphate on each glucopyranose unit included 2,3-di-O-methyl-6-sulphate-β-cyclodextrin (ME-CD-6-S; Regis Technologies Inc.; Morton Grove, IL, USA) and 2,6-di-O-methyl-3-sulphate-β-cyclodextrin (ME-CD-3-S; Cyclolab Ltd). Commercially available (2-carboxyethyl)-β-cyclodextrin (CE-CD containing, on average, three carboxyethyl groups; Sigma Chemical Company, St Louis, MO, USA), (2-hydroxypropyl)-β-cyclodextrin (HP-CD containing seven hydroxypropyl groups; Sigma Chemical Company) and 6-monodeoxy-6-monoamino-β-cyclo-dextrin (MA-CD having one -OH function replaced by -NH₂; Cyclolab Ltd) were used to synthesize the polysulphated β-cyclodextrins or sulphoalkyl-β-cyclodextrins.

Sulphating was achieved according to the procedure described by Astrup et al. [19]. The degree of substitution (DS) of the β-cyclodextrin derivatives was characterized by elemental analysis of C, N, H and S. The ratio of sulphur to carbon percentages was used to...
determine the DS of the \( \beta \)-cyclodextrin glucopyranose unit: 
\[
\text{DS} = \frac{\% \text{S} \times M_a (\text{C})}{\% \text{C} \times M_a (\text{S})} \times \text{total no. of C,}
\]
where \( M_a \) is the atomic mass (Table 1).

### Isolation of articular chondrocytes

Human articular chondrocytes were isolated as described elsewhere [20]. Briefly, human articular cartilage was obtained at total knee replacement surgery from femoral condyles and the tibial plateau of 15 different donors. None of them had received CSs or cytostatic drugs. Both visually intact and fibrillated OA cartilage samples were harvested separately and only OA cartilage was used for cell culture as OA progression involves the activities of auto/paracrine IL-1 activity [1] and previous experiments revealed definite effects of polysulphated polysaccharides on IL-1-primed chondrocytes after their isolation from normal cartilage [7]. The cartilage samples were diced into small fragments and the chondrocytes were isolated by sequential enzymatic digestion with hyaluronidase, pronase and collagenase. Isolated cells were then centrifuged for 10 min at 524 \( \times g \), washed three times in DMEM with 10% (v/v) fetal calf serum (FCS) and counted as described elsewhere, with some modifications [20, 21].

Chondrocytes were cultured in alginate beads to maintain their differentiated phenotype. The cultures were prepared as described elsewhere, with some modifications [20, 21]. Chondrocytes suspended in one volume of double-concentrated Hank’s balanced salts solution (HBSS) without calcium and magnesium (Gibco, Life Technologies, Paisley, UK) were carefully mixed with an equal volume of 2% (w/v) autoclaved alginate (low-viscosity alginate from Macrocystis pyrifera; Sigma) in HBSS. The final cell concentration was \( 5 \times 10^6 \) chondrocytes/ml in 1% alginate. The chondrocyte/alginate suspension was then slowly dripped through a 23-gauge needle into a 102-mM calcium chloride solution. The beads were allowed to polymerize for 10 min at room temperature. After removal of the calcium chloride, the beads were washed three times with 0.15 M sodium chloride. Alginate beads were cultured in 12-well plates with \( 1 \times 10^6 \) cells per culture (each well containing 20 alginate beads; ± 50 000 chondrocytes per bead) in 3 ml DMEM supplemented with 10% FCS and 50 mg ascorbate/ml at 37°C under 5% CO₂. Nutrient medium was replaced twice weekly. It has been shown that ECM metabolism by chondrocytes reaches steady state after 1 week in this alginate culture system [22].

### IL-6 release and ECM synthesis by chondrocytes after treatment with the differently sulphated \( \beta \)-cyclodextrins in vitro

Cartilage cells obtained from OA cartilage were used to evaluate the effect of the different \( \beta \)-cyclodextrin polysulphates on the synthesis and accumulation of ECM aggrecan. Fifteen donor samples allowed seven polysaccharides to be compared 6–11 times with the control situation. At Day 5 of culture, the OA chondrocytes of each donor were exposed to 5 \( \mu \)g/ml of, respectively, ME-CD, ME-CD-3-S, ME-CD-6-S, 6-monooamino-6-monoxy-\( \beta \)-CDPS (MA-CDPS), (2-carboxyethyl)-\( \beta \)-CDPS (CE-CDPS) and CDPS. After 5 additional culture days, media were collected and stored at –20°C. The cells were separated from their alginate coat by dissolving the alginate with 3 ml of 55-mM tri-sodium citrate dehydrate pH 6.8, 0.15 M NaCl at 25°C for 10 min. The resulting suspension was centrifuged at 524 \( \times g \) for 10 min to separate the supernatant containing the constituents of interterritorial matrix (IM) from the cells with their CAM. The aggrecan content (Biosource, Merelbeke, Belgium) in the IM was assayed by ELISA according to the manufacturer’s instructions. All experiments were performed in triplicate. Chondrocytes from four additional patients [mean (s.d.) 63.5 (9.3) years] were isolated and cultured as described above. After the culture period, Trizol (Invitrogen, Life Technologies, Paisley, UK) was added to the isolated cells. RNA was extracted and cDNA prepared as previously described [23]. Real-time PCR was performed using the ABI 7000 Sequence Detection System (Applied Biosystems, Carlsbad, CA, USA).

**Table 1 Chemical analysis of the different \( \beta \)-cyclodextrins**

| \( \beta \)-Cyclodextrin | C, % | H, % | N, % | S, % | S-substitution | DS/glucopyranose |
|--------------------------|------|------|------|------|---------------|-----------------|
| ME-CD                    | 0.00a| 1.00a|      |      |               |                 |
| Heptakis ME-CD-3-S       | 28.66| 4.50 | <0.05| 9.77 | 7.12          | 2.28            |
| Heptakis ME-CD-6-S       | 16.11| 2.28 | 0.47 | 16.34| 15.96         | 2.28            |
| Sulphated MA-CDPS        | 16.80| 2.63 | <0.05| 15.33| 17.34         | 2.47            |
| Sulphated CE-CDPS        | 18.91| 3.28 | <0.05| 16.40| 20.48         | 2.92            |
| Sulphated HP-CDPS        | 17.28| 2.86 | <0.05| 16.94| 15.41         | 2.21            |

*Manufacturer’s data. S-substitution: number of sulphate groups per \( \beta \)-cyclodextrin; DS/glucopyranose: sulphate groups per \( \beta \)-cyclodextrin glucopyranose unit.*
Cyclodextrins and blood coagulation activities

MA-CDPS, HP-CDPS, CE-CDPS and CDPS were prepared as buffered solutions at various concentrations. The polysaccharides were incubated with normal pooled plasma, prepared out of 40 healthy volunteers and analysed for their effects on aPTT, PT and fibrinogen levels on an STA Compact (Beckman Coulter, Analis, Belgium) coagulation analyser according to the manufacturer’s instructions.

β-Cyclodextrins and HIT

The activation of healthy donor thrombocytes by HIT patient anti-heparin/PF4 antibodies in the presence of heparin and the differently sulphated forms of β-cyclodextrin was tested. Plasma of patients that experienced HIT thromboembolic accidents following the administration of heparin and which showed anti-heparin/PF4 antibodies (HIT Abs) on immunological and flow cytometric tests [25–27] were selected for these analyses. The expression of CD62p by the activated platelets was assayed by means of flow cytometry with a FC500 Beckman Coulter (Beckman Coulter, Analis, Belgium).

Platelet-rich plasma (PRP) solution was prepared by slow centrifugation (10 min at 180 g) of fresh citrate anti-coagulated blood (1 : 9 v/v, 0.129 mol/l or 3.8% tri-sodium citrate buffer), obtained from normal donors. HIT Ab-positive plasma samples from patients and HIT Ab-negative control plasma from healthy donors were prepared by double centrifugation (15 min at 1157 g) of fresh citrate anti-coagulated blood. Seventy microlitres of PRP was incubated with 20 μl of HIT Ab containing plasma in the presence of different concentrations of heparin (0 and 0.31U/ml) or the different β-cyclodextrins (0 and 5 μg/ml). Experiments with each HIT Ab-positive plasma sample were repeated independently using thrombocytes of two donors (A and B), to avoid the possibility of non-reactive platelets.

Following the initial 40-min incubation step, 5 μl of the platelet solution were transferred to a fresh tube with 85 μl PBS containing 1% BSA and 0.1% sodium azide, 5 μl (0.25 μg) monoclonal anti-CD41 Abs [phycoerythrin (PE)-Texas Red energy coupled dye (ECD)-conjugated, Beckman Coulter] and 5 μl (0.125 μg) of anti-CD62p Ab (PE-conjugated, Beckman Coulter). CD41 (glycoprotein lib) is a selective marker of platelets and platelet precursors. CD62p is a constituent of α-granules and is released to the platelet surface on activation [12, 14].

After 20 min of incubation at room temperature, the total volume of the platelet suspension was adjusted to 600 μl buffered solution and evaluated without delay by flow cytometry. Twenty thousand events per sample were analysed and the platelet populations were gated by side scatter characteristics and the platelet marker CD41. Activated platelets (CD62p+) were distinguished from resting platelets by the CD62p-PE expression (Fig. 1). The fraction of activated platelets among the total platelet population was determined and relative CD62p ratios to the internal controls were calculated. [ratio: %CD62p+ (0.3 IU heparin or 5 μg/ml β-cyclodextrin derivate)/%CD62p+ (0 IU heparin or 0 μg/ml β-cyclodextrin derivate)]. Test results for the heparin-treated platelets were evaluated by a scoring system adapted from Jy et al. [14]. Control tests were scored positive when the calculated ratios of at least two donors were >2, which is based on previously obtained results with normal individuals.

To evaluate the potential of different β-cyclodextrins to induce platelet activation, both the percentages and ratios of CD62p+ platelets after incubation with the respective β-cyclodextrin were statistically compared with the percentage and the ratio of CD62p+ platelets after heparin incubation. The number of normal individuals who were tested with the β-cyclodextrin derivatives was too small to set a correct cut-off for these ratios.

Statistical analysis

To study the impact of the changes in the chondrocyte cultures after CDPS treatment, mean IL-6 and aggrecan concentrations were calculated from triplicate chondrocyte cultures after exposure to different CDPSs. Cross-reactivity with heparin of the polysaccharides on in vitro-induced platelet activation was analysed by Wilcoxon signed-rank test.

Results

Chemical analysis of the different β-cyclodextrins

From the data provided by the elemental analysis of the different β-cyclodextrin preparations (Table 1), ME-CD-6-S, as ME-CD-3-S, appeared to contain one sulphate group per glycopyranose unit. Sulphation occurred at positions 6 and 3 of each glycopyranose unit in ME-CD-6-S and ME-CD-3-S, respectively. HP-CDPS showed 2.92 sulphate groups per glycopyranose. Therefore, two
glucopyranose OH-functions, as well as the OH-function of the hydroxypropyl group, have been substituted by sulphate. Equally, CE-CDPS with glucopyranoses containing 2.47 sulphate groups had all remaining glucopyranose OH-functions substituted by sulphate. Although the sulphating procedure should have resulted in 3-sulphated glucopyranoses, degrees of sulphating of 2.28 and 2.21 of each glucopyranose were calculated for MA-CDPS and CDPS, respectively. To conclude, the in vitro tests were done with one unsulphated cyclodextrin: ME-CD, two monosulphated cyclodextrins sulphated on different C atoms: ME-CD-3-S and -6-S and 4 CDPSs with degrees of sulphating ranging from 2 to 3: CDPS, MA-, CE- and HP-CDPS. Chemical structures of the different CDPS are given in Fig. 2.

Effects on ECM production and inhibition of IL-6 release by differently sulphated β-cyclodextrins

The unsulphated ME-CD failed to promote aggrecan synthesis or to affect IL-6 release and was used as a control in the experiments on isolated chondrocytes. Furthermore, the monosulphated cyclodextrins ME-CD-3-S and -6-S also failed to affect chondrocyte aggrecan synthesis and IL-6 secretion. The bisulphated (CDPS, MA-CDPS) and trisulphated β-cyclodextrins (HP-CDPS, CE-CDPS), however, significantly enhanced chondrocyte aggrecan synthesis. When compared with the controls, average percentage increases of 51.6 ($P=0.009$), 41.0% ($P=0.006$), 30.4% ($P=0.020$) and 67.3% ($P=0.007$) for CDPS, MA-CDPS, HP-CDPS and CE-CDPS, respectively, were noted (Fig. 3A). These highly sulphated β-cyclodextrins significantly repressed chondrocyte IL-6 secretion by ~25% with $P<0.001$ for the four polysaccharides tested (Fig. 3B). Based on the results of the blood coagulation and HIT-analysis, CE-CDPS was selected for further analysis on chondrocyte metabolism. qPCR analyses were performed of additional ECM genes (COL2A1, aggrecan, COL1A1), catabolic enzymes and enzyme inhibitors (ADAMT55, MMP2, TIMP-1), transcription factors (SOX-9) and growth factors (Bone Morphogenetic Protein 2) to provide further insights into the effect of CE-CDPS on chondrocyte metabolism. In parallel, with the ELISA analysis mentioned above, aggrecan gene expression was elevated in three of four patients analysed. No effects were observed on collagen expression (COL2A1 and COL1A1). The MMP-2 enzyme showed a lower expression upon stimulation with CE-CDPS in three patients (in one of the patients no expression of MMP2 could be detected). Upon CE-CDPS stimulation, a significant elevated expression was observed for the transcription factor SOX-9 (on average 3.2-fold induction), confirming the positive effect of CE-CDPS on the chondrocyte’s anabolic activity (Fig. 3C–E).

β-Cyclodextrin effects on blood coagulation activities

With increasing concentrations, the aPTT values stagnated up to a concentration of 5 μg/ml for all the CDPS derivatives studied. Above 50 μg/ml no clot formed for the
Fig. 2 Chemical structures of β-cyclodextrin derivatives.

ME-CD R= [-CH₃]₂₁ or [-SO₃]₁₅
ME-CD-3S R= [-CH₃]₁₄ or [-SO₃]₁₈
ME-CD-6S R= [-CH₃]₁₄ or [-SO₃]₁₈
MA-CDPS R= [-NH₂]₁ or [-SO₃]₁₆ or H₆
CE-CDPS R= [-CH₂CH₂COOH]₃ or [-SO₃]₁₈
HP-CDPS R= [-CH₂CHOSO₃CH₃]₇ or [-SO₃]₁₄
CDPS R= [-SO₃]₁₅ or H₆

Fig. 3 (A) Percentage changes in aggrecan production by OA chondrocytes treated with β-CDPS derivatives. Dots represent mean values of triplicate cultures of one patient. Lines represent the overall mean. (B) Percentage changes in IL-6 release by OA chondrocytes treated with β-CDPS derivatives. Dots represent mean values of triplicate cultures of one patient. Lines represent the overall mean. (C–E) Relative expression of aggrecan, MMP2 and SOX-9, respectively, as determined by qPCR. Four additional patient samples were stimulated with CE-CDPS and compared with controls. Dots represent the mean expression of duplicate cultures. No expression of MMP2 was observed in one of the samples.
derivatives studied in the observation time of the experiment (Fig. 4A). The same tendency was observed for PT values, except for the far more limited increase in PT for concentrations >50 µg/ml (Fig. 4B). Minor decreases were observed in fibrinogen concentrations (mg/ml) after incubation with 50 or 100 µg/ml of MA-CDPS, HP-CDPS, CE-CDPS or CDPS, respectively (Fig. 4C). No influence on the blood coagulation cascade could thus be detected at concentrations that highlighted a chondroprotective effect in vitro.

Induction of platelet activation

All HIT Ab-positive plasma samples showed platelet heparin activation ratios %CD62p⁺ (0.3 IU heparin)/%CD62p⁺ (0 I U heparin) >2 for the two donors, indicating an activation of platelets by heparin/PF4 antibodies. Platelets were not activated by heparin or any of the β-CDPS derivatives in the absence of patient’s HIT Ab (data not shown).

Immunological cross-reactivity between heparin and some of the polysulphated β-cyclodextrins became evident as HP-CDPS, MA-CDPS and CDPS induced platelet activation in the presence of the plasma samples of the individuals that had developed HIT Ab upon previous exposure to heparin (Fig. 1). Paired analysis of both ratios and percentages of CD62p⁺ cells confirmed a significant difference (P = 0.017 for percentages and P = 0.012 for ratios) between heparin and CE-CDPS-incubated platelets, indicating that CE-CDPS exhibited no cross-reactivity with the heparin/PF4 antibodies (Table 2). Moreover, the P-values calculated from the paired analysis of ratios and percentages of activated platelets between CE-CDPS and each of the other analysed cyclodextrins was <0.05.

**Fig. 4** Effects of the β-CDPS derivatives on variables of plasma coagulation activity in a pool of 40 serum samples. The assays were done once as the results of these types of tests are particularly consistent. (A) aPTT, in s; (B) PT, in s; and (C) fibrinogen, in mg/ml; abscissa: sulphated cyclodextrins, in µg/ml.

**Discussion**

Among the polysulphated polysaccharides shown to improve connective tissue cell ECM metabolism in vitro and in vivo [4–10], chondroitin polysulphate was mainly found to be applicable in the treatment of osteoarticular pathology. The safety of this drug in human clinics, however, became controversial. The purpose of this study was, therefore, to search for more advanced polysaccharide polysulphates with a preserved chondroprotective capacity, a reduced effect on coagulation and, imperatively, a reduced risk for HIT.

The structure-modifying capacities of CDPS have been evidenced previously. In vitro, all three α-, β- and γ-CDPS equally and significantly improved the synthesis and accumulation by chondrocytes of CAM macromolecules e.g. aggrecan, Type II collagen and fibronectin [17]. It was shown that this enhanced repair function resulted from a down-modulation of the autocrine catabolic IL-1 pathway: β-CDPS inhibited the synthesis of IL-6 in both normal and OA chondrocytes. Although the experiments were not performed in the presence of IL-1-blocking antibodies, it is supposed that β-cyclodextrin affected the IL-1 loop and did not directly impede the production of IL-6 [17]. While in osteoarthritic chondrocytes both autocrine anabolic (IGF-1) and catabolic (IL-1) pathways are up-regulated, the selective inhibition of IL-1 resulted in a dramatic improvement of the repair function. In vivo, this repair-promoting effect was obvious when rabbits, in which the anterior cruciate ligament of the knees were sectioned, failed to develop cartilage degradation when treated with s.c. injections of 1 mg/kg γ-CDPS once weekly [18]. In these in vivo experiments, however, a 15-times higher dose (5 mg/kg s.c. three times weekly) caused haemorrhages in some of the treated animals and a 90-times higher dose (30 mg/kg s.c. three times weekly) even caused fatal haemorrhages in most animals [18]. A series of polysulphated cyclodextrin derivatives were thus synthesized to come across potentially less harmful treatments. β-Cyclodextrins with different alkyl substitutions on distinct –OH groups allowed for the
synthesis of differently sulphated β-cyclodextrins with different biological activities and toxicological profiles. The introduction of distinct alkyl groups on the β-cyclodextrin glucopyranose unit, for example, did not prolong the aPTT in vitro, suggesting a reduced anti-coagulant activity compared with CDPS [28, 29]. These compounds were tested in vitro, indicating that monosulphated β-cyclodextrins with different sulphated chains on the β-cyclodextrin ring—irrespective of their position or spacing—was necessary to block down-stream IL-1 events and to warrant an enhancement of the chondrocyte’s anabolic function. It was concluded that the introduction of alkyl groups was of minor importance compared with the degree of sulphating, when cartilage protection was considered. Additional experiments confirmed the positive effect of CE-CDPS, mainly, on the chondrocyte’s anabolic activity (SOX-9, aggrecan). On the catabolic side, MMP2 expression was slightly decreased upon CE-CDPS stimulation. To provide in-depth insights on the potential anti-catabolic activity of CE-CDPS, future experiments on cell cultures co-stimulated with pro-inflammatory cytokines are warranted.

The in vitro tests with MA-CDPS, HP-CDPS, CE-CDPS and CDPS on blood coagulation revealed dose-related anti-coagulant effects but no remarkable mutual difference between the derivatives. At presumed therapeutic concentrations (5 μg/ml in vitro), none of the polysulphated β-cyclodextrin derivatives revealed an inhibition of the blood coagulation cascade. Moreover, MA-CDPS, HP-CDPS and CDPS showed an interaction with the heparin/PF4 antibodies, triggering activation of the platelets. Introduction of an average of three carboxyethyl chains on the β-cyclodextrin ring, in contrast, significantly decreased platelet activation in comparison with heparin and the other β-CDPS derivatives (P < 0.05) in this in vitro model of HIT, indicating that CE-CDPS exhibits no cross-reactivity with the heparin/PF4 antibodies.

In vitro testing of the interaction of CDPS derivatives with HIT Ab-positive sera in some way constrain the conclusions of the present study. There are no data available on the ability of the derivatives to induce autoimmune antibodies in vivo themselves. A previously published case report on the induction of HIT after chondroitin polysulphate therapy showed antibodies directed against epitopes of chondroitin polysulphate, but HIT only developed after an additional heparin treatment, which suggests cross-reactivity [13]. These data suggest the potential of polysulphated polysaccharides to induce auto-antibodies although these polysaccharides do not invariably induce HIT themselves. Nevertheless, being low-molecular weight polysaccharides, the possible occurrence of HIT following the administration of CDPS in vivo may be less probable as classical HIT rarely occurred with low-molecular weight forms of heparin.

In summary, these studies aimed at revealing more advanced polysaccharide polysulphates with chondroprotective capacities. We showed that poly- but not

### Table 2  Platelet activation by heparin and polysulphated β-cyclodextrin derivatives

| Treatment | Patient 1 | Patient 2 | Patient 3 | Patient 4 | P-values | Heparin | MA-CDPS | CE-CDPS | HP-CDPS |
|-----------|-----------|-----------|-----------|-----------|----------|---------|---------|---------|---------|
| Heparin   |           |           |           |           |          |         |         |         |         |
| ΔCD62p+ % | 45.5      | 14.3      | 45.6      | 15.1      | 60.3     | 42.3    | 34.8    | 56.4    | Reference |
| Ratio     | 4.2       | 2.2       | 2.8       | 3.9       | 4.3      | 8.2     | 2.7     | 2.8     | Reference |
| MA-CDPS   |           |           |           |           |          |         |         |         |         |
| ΔCD62p+ % | 74.8      | 69.9      | 9.6       | 17.4      | 16.7     | 32.6    | 51.1    | 63.6    | 0.779 Reference |
| Ratio     | 5.2       | 5.5       | 1.4       | 3.5       | 1.9      | 8.2     | 3.5     | 3.1     | 0.779 Reference |
| CE-CDPS   |           |           |           |           |          |         |         |         |         |
| ΔCD62p+ % | 13.9      | 14.4      | 2.4       | 1.1       | 7.9      | 10.2    | 22.9    | 45.0    | 0.017 0.012 Reference |
| Ratio     | 1.8       | 2.2       | 1.1       | 1.2       | 1.4      | 2.7     | 2.2     | 2.4     | 0.012 0.012 Reference |
| HP-CDPS   |           |           |           |           |          |         |         |         |         |
| ΔCD62p+ % | 67.6      | 53.0      | 0.1       | 1.2       | 23.3     | 17.1    | 63.2    | 60.7    | 0.779 0.123 0.025 Reference |
| Ratio     | 4.9       | 5.1       | 1         | 1.1       | 2.1      | 4.7     | 4.6     | 2.8     | 0.484 0.123 0.036 Reference |
| CDPS      |           |           |           |           |          |         |         |         |         |
| ΔCD62p+ % | 76.1      | 73.1      | 27.5      | -2.8      | 42.7     | 34.1    | 63.5    | 58.1    | 0.484 0.327 0.017 0.093 Reference |
| Ratio     | 5.8       | 6.5       | -         | 0.7       | 2.5      | 7       | 4.4     | 2.5     | 0.889 0.889 0.025 0.123 Reference |

Platelets from two different donors (dA and dB) were incubated with plasma samples containing HIT ab from four patients (Patients 1, 2, 3 and 4) and with the different sulphated polysaccharides. ΔCD62p+ %: percentage increases in CD62p+ platelets; ratio: %CD62p+ (0.3 IU heparin or 5 μg/ml sulphated polysaccharide)/ %CD62p+ (0 IU heparin or 0 μg/ml sulphated polysaccharide).
monosulphated β-cyclodextrins can restore ECM repair potential of OA chondrocytes in vitro. From these polysulphated β-cyclodextrin derivatives, CE-CDPS had a better safety profile when the in vitro induction of HIT was considered. Additional preclinical studies in models of OA are underway to evaluate the in vivo chondroprotective efficacy of CE-CDPS.

Rheumatology key messages

- CDPSs restore synthesis of ECM molecules of OA chondrocytes, depending on the sulphation degree.
- Carboxyethyl-β CDPS can restore OA chondrocyte metabolism without enhanced risk of HIT.

Acknowledgements

The authors would like to thank Katrien Van Beneden from the Department of Rheumatology, Ghent University Hospital for scientific support and Prof. Dr K. F. Almqvist and Dr P. Verdonk from the Department of Orthopaedic Surgery, Ghent University Hospital, for collecting the articular cartilage samples. We wish to thank B.V.C. for statistical analyses. David Cullis-Hill (Biopharm Pty Ltd, NSW, Australia) produced the pyrogen-free CDPS derivatives.

Funding: This work was supported by the Flemish Scientific Research Foundation (FWO B/05764/02-04) and the Ghent University Research Foundation (BOF/07/GOA/002 B/07800/02).

Disclosure statement: D.E. and G.V. have filed a patent on the therapeutic use of alkylated CDPSs. All other authors have declared no conflicts of interest.

References

1. Wang J, Verdonk P, Elewaut D, Veys EM, Verbruggen G. Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage 2003;11:801–9.

2. Middleton J, Manthey A, Tyler J. Insulin-like growth factor (IGF) receptor, IGF-1, interleukin-1 beta (IL-1 beta), and IL-6 mRNA expression in osteoarthritic and normal human cartilage. J Histochem Cytochem 1996;44:133–41.

3. Chambers MG, Bayliss MT, Mason RM. Chondrocyte cytokine and growth factor expression in murine osteoarthritis. Osteoarthritis Cartilage 1997;5:301–8.

4. Schwartz NB, Dorfman A. Stimulation of chondroitin sulfate proteoglycan production by chondrocytes in monolayer. Connect Tissue Res 1975;3:115–22.

5. Verbruggen G, Veys EM. Influence of sulphated glycosaminoglycans upon proteoglycan metabolism of the synovial lining cells. Acta Rheumatol Belg 1977;1:75–92.

6. Verbruggen G, Cornelissen M, Elewaut D, Broddez C, De Ridder L, Veys EM. Influence of polysulfated polysaccharides on aggrecans synthesized by differentiated human articular chondrocytes. J Rheumatol 1999;26:1663–71.

7. Wang L, Wang J, Almqvist KF, Veys EM, Verbruggen G. Influence of polysulfated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. Clin Exp Rheumatol 2002;20:669–76.

8. Verbruggen G, Veys EM. Influence of an oversulphated heparinoid upon hyaluronate metabolism of the human synovial cell in vivo. J Rheumatol 1979;6:554–61.

9. Verbruggen G, Veys EM. Intra-articular injection pentosanpolysulphate results in increased hyaluronan molecular weight in joint fluid. Clin Exp Rheumatol 1992;10:249–54.

10. Francis DJ, Hutadilok N, Kongtawelet P, Ghosh P. Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int 1993;13:61–4.

11. Amiral J, Bridey F, Wolf M et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21–8.

12. Vitale M, Tazzari P, Ricci F et al. Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry 2001;46:290–5.

13. Greinacher A, Michels I, Schafer M, Kiefel V, Mueller-Eckhardt C. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol 1992;81:252–4.

14. Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS. A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999;82:1255–9.

15. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004;164:361–9.

16. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002;21:231–43.

17. Verdonk P, Wang J, Groeneboer S et al. Cyclodextrin polysulphates repress IL-1 and promote the accumulation of chondrocyte extracellular matrix. Osteoarthritis Cartilage 2005;13:887–95.

18. Groeneboer S. Cyclodextrin polysulphate protects articular cartilage in experimental lapine knee osteoarthritis. Osteoarthritis Cartilage 2008;16:986–93.

19. Astrup T, Galsmar IB, Volkert M. Polysaccharide sulphate as anticoagulants. Acta Physiol Scand 1944;8:215–26.

20. Verbruggen G, Wang J, Wang L, Elewaut D, Veys EM. Analysis of chondrocyte functional markers and pericellular matrix components by flow cytometry. In: Sabatini M, Pastoureau P, De Ceuninck F, eds. Cartilage and osteoarthritis: cellular and molecular tools. Totowa, NJ: Humana Press, 2004.

21. Guo JF, Jourdian GW, MacCallum DK. Culture and growth characteristics of chondrocytes encapsulated in alginate beads. Connect Tissue Res 1989;19:277–97.
22 Wang J, Elewaut D, Veys EM, Verbruggen G. Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum 2003;48:1281–91.

23 Lambrecht S, Verbruggen G, Elewaut D, Deforce D. Differential expression of alphaB-crystallin and evidence of its role as a mediator of matrix gene expression in osteoarthritis. Arthritis Rheum 2009;60:179–88.

24 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–8.

25 Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148–57.

26 Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259–69.

27 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535–55.

28 Rajewski RA, Traiger G, Bresnahan J, Jabaroansari P, Stella VJ, Thompson DO. Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci 1995;84:927–32.

29 Meneveau NF, Klugherz BD, Chaqour B et al. Beta-cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury. Coron Artery Dis 2002;13:189–97.